inflammasome-mediated dysbiosis regulates progression nafld obesity 
non-alcoholic fatty liver disease nafld hepatic manifestation metabolic syndrome leading cause chronic liver disease western world twenty per cent nafld individuals develop chronic hepatic inflammation non-alcoholic steatohepatitis nash associated cirrhosis portal hypertension hepatocellular carcinoma yet causes progression nafld nash remain obscure show nlrp6 nlrp3 inflammasomes effector protein il negatively regulate nafld/nash progression well multiple aspects metabolic syndrome via modulation gut microbiota different mouse models reveal inflammasome-deficiency-associated changes configuration gut microbiota associated exacerbated hepatic steatosis inflammation influx tlr4 tlr9 agonists portal circulation leading enhanced hepatic tumour-necrosis factor tnf-alpha expression drives nash progression furthermore co-housing inflammasome-deficient mice wild-type mice results exacerbation hepatic steatosis obesity thus altered interactions gut microbiota host produced defective nlrp3 nlrp6 inflammasome sensing may govern rate progression multiple metabolic syndrome-associated abnormalities highlighting central role microbiota pathogenesis heretofore seemingly unrelated systemic auto-inflammatory metabolic disorders 
